9LB 주식 개요 임상 단계의 바이오 제약 회사인 레전드 바이오테크는 자회사를 통해 미국, 중국 및 전 세계에서 종양학 및 기타 적응증을 위한 새로운 세포 치료제의 발견, 개발, 제조 및 상용화에 관여하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Legend Biotech Corporation 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Legend Biotech 과거 주가 현재 주가 US$32.20 52주 최고치 US$64.50 52주 최저치 US$30.80 베타 0.16 1개월 변경 -18.27% 3개월 변경 사항 -29.07% 1년 변경 사항 -39.25% 3년 변화 -21.84% 5년 변화 n/a IPO 이후 변화 34.17%
최근 뉴스 및 업데이트
Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study Dec 10
Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023) Nov 14
Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI® Nov 05
New minor risk - Share price stability Sep 27
Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024 Sep 23
Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients Aug 28 더 많은 업데이트 보기
Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study Dec 10
Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023) Nov 14
Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI® Nov 05
New minor risk - Share price stability Sep 27
Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024 Sep 23
Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients Aug 28
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$1.14 loss in 2Q 2023) Aug 11
Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024 Aug 09
Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma Jul 02
Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA Jun 05
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA May 24
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.68 loss in 1Q 2023) May 13
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma Apr 23
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma Mar 16
Full year 2023 earnings released: US$2.94 loss per share (vs US$2.81 loss in FY 2022) Mar 12
Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma Jan 25
Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) Dec 22
Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study Dec 12
Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.68 loss in 3Q 2022) Nov 21
Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023 Aug 22
Second quarter 2023 earnings released: US$1.14 loss per share (vs US$1.25 loss in 2Q 2022) Aug 16
Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel) Jun 07
Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study Jun 06
Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel) May 26
First quarter 2023 earnings released: US$0.68 loss per share (vs US$0.27 loss in 1Q 2022) May 18
Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings May 17 Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million. May 10
Full year 2022 earnings released Mar 31
Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021) Feb 18 Legend Biotech Corporation Announces Research and Development Update
Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC Jan 10
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China Jan 03
Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer Nov 22
High number of new and inexperienced directors Nov 16
Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022 Nov 04
Legend Biotech Corporation Elects Philip Yau as Director Oct 18
Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Sep 28
Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022 Sep 17
Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 06
Legend Biotech Corporation Announces Board Changes Aug 05 Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million. Jul 29
Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million. Jul 28
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021) Jul 27
Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901 Jul 08
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma Jun 05
Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers Jun 04
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021) Jun 02
European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation May 27 Legend Biotech Appoints Lori Macomber as Chief Financial Officer May 10
High number of new and inexperienced directors Apr 27
Legend Biotech Announces Executive Changes Apr 04
Legend Biotech Corporation Announces Appointment of Guowei Fang as Global Head of Research and Early Development Apr 03
Full year 2021 earnings released: US$2.74 loss per share (vs US$2.57 loss in FY 2020) Apr 02
Legend Biotech Corporation's CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma Mar 02
Legend Biotech Announces FDA Clinical Hold of Its Phase 1 Clinical Trial for LB1901 Feb 16
Forecast to breakeven in 2024 Jan 01
Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $300 million. Dec 18
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Dec 17
Legend Biotech Corporation Announces New and Updated Results from the Cartitude Clinical Development Program Studying Ciltacabtagene Autoleucel (Cilta-Cel) in the Treatment of Multiple Myeloma, Which Were Presented At the 63Rdamerican Society of Hematology (Ash) Annual Meeting and Exposition Dec 15
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen Dec 07
No longer forecast to breakeven Nov 27
Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.50 loss in 3Q 2020) Nov 17
Forecast to breakeven in 2023 Oct 20
Forecast to breakeven in 2023 Sep 23
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-Cd4 Car-T Therapy for Relapsed or Refractory T-Cell Lymphoma Sep 14
Second quarter 2021 earnings released: US$0.66 loss per share (vs US$1.25 loss in 2Q 2020) Aug 25
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings Jun 02
Genscript Biotech Corporation and Legend Biotech Corporation Announce New and Updated Results for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA-Directed CAR-T Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma to be Featured at the 2021 ASCO Annual Meeting and at the EHA Virtual Congress May 29
Legend Biotech Corporation Announces U.S. Food and Drug Administration Grants Bcma Car-T Cilta-Cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma May 27
Legend Biotech Corporation Announces EMA Acceptance of the MAA for Cilta-Cel for RRMM May 21
First quarter 2021 earnings released: US$0.61 loss per share (vs US$0.44 loss in 1Q 2020) May 18
Forecast to breakeven in 2024 May 18
Legend Biotech Corporation Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings May 13
Legend Biotech Announces Submission of European Marketing Authorisation Application for Bcma Car-T Therapy Ciltacabtagene Autoleucel (Cilta-Cel) for the Treatment of Relapsed And/Or Refractory Multiple Myeloma May 01
Full year 2020 earnings released: US$2.57 loss per share (vs US$1.33 loss in FY 2019) Apr 06
Full year 2020 earnings released: US$2.57 loss per share (vs US$1.33 loss in FY 2019) Mar 19
Legend Biotech Corporation to Report Q4, 2020 Results on Mar 18, 2021 Mar 11
New 90-day low: €20.00 Mar 05 주주 수익률 9LB DE Biotechs DE 마켓 7D 1.9% 5.8% 2.0% 1Y -39.2% -6.1% 9.6%
전체 주주 수익률 보기
수익률 대 산업: 9LB 지난 1년 동안 -6.1 %를 반환한 German Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 9LB 지난 1년 동안 9.6 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 9LB's price volatile compared to industry and market? 9LB volatility 9LB Average Weekly Movement 7.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: 9LB 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 9LB 의 주간 변동성 ( 7% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 바이오 제약 회사인 레전드 바이오테크는 자회사를 통해 미국, 중국 및 전 세계에서 종양학 및 기타 적응증을 위한 새로운 세포 치료제의 발견, 개발, 제조 및 상용화에 관여하고 있습니다. 주요 제품 후보인 LCAR- B38M은 다발성 골수종(MM) 치료를 위한 키메라 항원 수용체입니다. 또한 비호지킨 림프종, 급성 림프모구 백혈병, 위암, 식도암, 췌장암, 대장암, 간세포암, 소세포폐암, 비소세포폐암 등 다양한 암을 대상으로 하는 초기 단계의 자가 CAR-T 제품 후보 포트폴리오를 보유하고 있습니다.
자세히 보기 Legend Biotech Corporation 기본 사항 요약 Legend Biotech 의 수익과 매출은 시가총액과 어떻게 비교하나요? 9LB 기본 통계 시가총액 €5.95b 수익(TTM ) -€336.19m 수익(TTM ) €502.34m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 9LB 손익 계산서(TTM ) 수익 US$520.18m 수익 비용 US$607.90m 총 이익 -US$87.72m 기타 비용 US$260.41m 수익 -US$348.13m
주당 순이익(EPS) -1.90 총 마진 -16.86% 순이익 마진 -66.92% 부채/자본 비율 26.6%
9LB 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/08 23:06 장 마감 주가 2025/01/07 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Legend Biotech Corporation 27 애널리스트 중 20 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ishan Majumdar Baptista Research Huidong Wang Barclays Konstantinos Biliouris BMO Capital Markets Equity Research
24 더 많은 분석가 보기 